LOTTE Holdings Healthcare and Biopharmaceutical Corporate Venture Capital
Overview
LOTTE Holdings Healthcare and Biopharmaceutical Corporate Venture Capital (CVC) is the corporate venture capital arm of LOTTE Holdings, established in August 2024 to invest in biopharmaceuticals and next-generation healthcare technologies. The CVC aims to accelerate access to innovative technologies and promote investment in promising startups globally. Its mission is to improve people's well-being by supporting and investing in startup companies developing innovative healthcare technologies to save patients' lives. The CVC focuses on various stages of investment, including seed, early stage, Series A, Series B, growth, late stage, and pre-IPO, targeting companies in Japan, South Korea, the United States, and globally. It invests in a wide range of industries within the healthcare and biopharmaceutical sectors, such as medical devices, biotechnology, pharmaceuticals, medical research, diagnostics, therapeutics, medical technology, healthtech, medtech, pharmaceutical manufacturing, clinical trials, and regenerative medicine. By leveraging the extensive capabilities of the LOTTE Group, including LOTTE Biologics and its global networks, the CVC supports the transformation of innovative ideas into practical solutions for current and emerging challenges in human health. This strategic approach underscores LOTTE Holdings' commitment to advancing healthcare innovation and addressing global health challenges through strategic investments in exceptional startups.
Investment Focus
- Innovative healthcare technologies
- Biopharmaceutical advancements
- Global market potential
- Scalable business models
- Experienced management teams
- Regulatory compliance
- Strong intellectual property portfolios
- Clear exit strategies
- Alignment with LOTTE Holdings' mission
- Potential for significant social impact
- Sustainable business practices
- Competitive market positioning
- Proven product efficacy
- Established customer base
- Scalable operations
Portfolio Companies
Reach LOTTE Holdings Healthcare and Biopharmaceutical Corporate Venture Capital directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about LOTTE Holdings Healthcare and Biopharmaceutical Corporate Venture Capital
What sectors does LOTTE Holdings Healthcare and Biopharmaceutical Corporate Venture Capital invest in?
LOTTE Holdings Healthcare and Biopharmaceutical Corporate Venture Capital invests in Healthcare, HealthTech, Pharmaceuticals, Medical Devices, Diagnostics and Medtech, and is based in Tokyo, Japan. LOTTE Holdings Healthcare and Biopharmaceutical Corporate Venture Capital is listed as a corporate vc in the ConnectSafely investor database.
What stage does LOTTE Holdings Healthcare and Biopharmaceutical Corporate Venture Capital invest at?
LOTTE Holdings Healthcare and Biopharmaceutical Corporate Venture Capital backs companies at Seed, Early Stage, Series A, Series B, Growth and Late Stage, writing cheques of 1M - 50M.
Which regions does LOTTE Holdings Healthcare and Biopharmaceutical Corporate Venture Capital invest in?
LOTTE Holdings Healthcare and Biopharmaceutical Corporate Venture Capital invests across United States, Japan, South Korea and Global.
What companies has LOTTE Holdings Healthcare and Biopharmaceutical Corporate Venture Capital invested in?
LOTTE Holdings Healthcare and Biopharmaceutical Corporate Venture Capital's portfolio includes Nuvig Therapeutics, Cartography Biosciences and Physiologas Technologies.
Last updated · Source: ConnectSafely investor database
